Segment Information -Net Sales and Segment Contribution for Each Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Net sales	$ 81,712	$ 67,689	$ 234,645	$ 193,466
Cost of sales	14,790	12,188	40,792	33,947
Selling, general and administrative expense	52,571	53,475	156,773	158,838
Research and development expense	3,175	5,953	18,168	17,429
Restructuring	208	0	3,464	0
Amortization of intangible assets	190	175	570	519
Investigation, restatement and related expense	(38)	3,001	4,652	8,771
Operating income (loss)	10,816	(7,103)	10,226	(26,038)
Supplemental information
Depreciation expense	653	831	2,054	2,549
Share-based compensation	4,388	2,372	12,793	10,798
Corporate & Other
Segment Reporting Information [Line Items]
Net sales	1,336	816	3,179	2,169
Cost of sales	1,485	1,029	3,419	2,821
Selling, general and administrative expense	13,884	17,945	41,920	50,582
Research and development expense	0	0	0	0
Restructuring	0		0
Amortization of intangible assets	190	175	570	519
Supplemental information
Depreciation expense	230	344	711	1,065
Share-based compensation	2,486	80	7,404	4,279
Wound & Surgical | Operating Segments
Segment Reporting Information [Line Items]
Net sales	80,376	66,873	231,466	191,297
Cost of sales	13,305	11,159	37,373	31,126
Selling, general and administrative expense	38,687	35,530	114,853	108,256
Research and development expense	3,175	1,680	6,330	6,068
Restructuring	0		0
Amortization of intangible assets	0	0	0	0
Segment contribution	25,209	18,504	72,910	45,847
Supplemental information
Depreciation expense	423	451	1,208	1,364
Share-based compensation	1,902	1,945	5,130	5,609
Regenerative Medicine | Operating Segments
Segment Reporting Information [Line Items]
Net sales	0	0	0	0
Cost of sales	0	0	0	0
Selling, general and administrative expense	0	0	0	0
Research and development expense	0	4,273	11,838	11,361
Restructuring	208		3,464
Amortization of intangible assets	0	0	0	0
Segment contribution	(208)	(4,273)	(15,302)	(11,361)
Supplemental information
Depreciation expense	0	36	135	120
Share-based compensation	$ 0	$ 347	$ 259	$ 910